EpiAxis Therapeutics is delighted to announce its participation in the Venture & Capital Sydney investor conference, scheduled for Thursday, 3 August 2023.
The event will be held at Hilton Sydney, located at 488 George St, Sydney NSW, from 9am to 6pm. This conference provides a fantastic opportunity to connect with investors and our CEO Dr Jeremy Chrisp would be delighted to speak with attendees at the event.
Venture and Capital 2023 is an exclusive conference designed to empower high-net-worth VCs, Family Offices and professional investors lwith unparalleled access to investment opportunities and exclusive networking.
EpiAxis will be highlighting its disruptive epigenetic approach to overcome treatment resistance and prevent cancer recurrence at the conference.
Learn more about Venture & Capital Sydney here.
Contact Dr Jeremy Chrisp at firstname.lastname@example.org
Additionally, Dr Chrisp was recently interviewed by Wholesale Investor, where he discussed the company’s mission and ground-breaking work. Dr Chrisp talked to Wholesale Investor’s Rhythm Gupta about EpiAxis’ innovative approach to overcoming treatment resistance and preventing cancer recurrence.
Watch the interview here: